Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648325 | 0.88 | PDPK1 (0.39) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL6954571 | 0.79 | TNK2 (0.53) | TNK2MTORTNKSTNKS2PDPK1 | |
| SCHEMBL8399665 | 0.75 | TNK2 (0.63) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL8406159 | 0.68 | TNK2 (0.39) | TNK2LMNAMTOR | |
| SCHEMBL8071811 | 0.68 | TNK2 (0.52) | TNK2MTORPDPK1ABL1EGFR | |
| SCHEMBL8393648 | 0.65 | LMNA (0.58) | CYP2D6CYP3A4CYP2C19MEN1MAPT | |
| SCHEMBL1129645 | 0.65 | TNK2 (0.73) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL1129273 | 0.65 | TNK2 (0.73) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL13668665 | 0.64 | TPSAB1 (0.54) | TNK2CYP2D6CYP3A4CYP2C19MEN1 | |
| SCHEMBL1130765 | 0.64 | TNK2 (1.00) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | TNK2 144/4885HTR7 3986/4885HTR6 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.